Cite
MLA Citation
C. Gabay et al.. “LB0003 Tocilizumab (TCZ) monotherapy is superior to adalimumab (ADA) monotherapy in reducing disease activity in patients with rheumatoid arthritis (RA): 24-week data from the phase 4 adacta trial.” Annals of the rheumatic diseases, vol. 71, n.d., p. 152. http://access.bl.uk/ark:/81055/vdc_100136718213.0x000061